We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Immunovaccine Signs Research Agreement with OncoTherapy Science
News

Immunovaccine Signs Research Agreement with OncoTherapy Science

Immunovaccine Signs Research Agreement with OncoTherapy Science
News

Immunovaccine Signs Research Agreement with OncoTherapy Science

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Immunovaccine Signs Research Agreement with OncoTherapy Science"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Peptide antigens hold the promise of high efficacy and low toxicity. Yet the impact of peptides as an effective means for cancer treatment has been limited, mainly due to the low immunogenicity of peptides. OncoTherapy Science's novel cancer peptides have the potential to function as unique targets for the anti-angiogenic therapy of cancer. The advantage of developing a vaccine formulation using Immunovaccine's DepoVax™ delivery platform is its ability to generate a depot effect that enhances the immunogenicity of peptides in preclinical models.

"We are pleased to be collaborating with OncoTherapy Science and evaluating how our DepoVax™ technology may enhance the potential of these select peptide antigens to create a highly potent, highly specific vaccine candidate," remarked Dr. Marc Mansour, Vice President of R&D at Immunovaccine.

Advertisement